Veracyte (Veracyte) Retained Earnings : $-468.1 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Veracyte Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Veracyte's retained earnings for the quarter that ended in Dec. 2023 was $-468.1 Mil.

Veracyte's quarterly retained earnings declined from Jun. 2023 ($-410.2 Mil) to Sep. 2023 ($-439.8 Mil) and declined from Sep. 2023 ($-439.8 Mil) to Dec. 2023 ($-468.1 Mil).

Veracyte's annual retained earnings declined from Dec. 2021 ($-357.2 Mil) to Dec. 2022 ($-393.7 Mil) and declined from Dec. 2022 ($-393.7 Mil) to Dec. 2023 ($-468.1 Mil).

Veracyte Retained Earnings Historical Data

The historical data trend for Veracyte's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte Retained Earnings Chart

Veracyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-246.69

-281.59

-357.16

-393.72

-468.12

Veracyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															-393.72	-401.81	-410.21	-439.83	-468.12

Veracyte Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Veracyte (NAS:VCYT) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Veracyte (Veracyte) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (NAS:VCYT) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

12V:Germany

Address

6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.veracyte.com

Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis products.

Executives

Phillip G. Febbo	officer: Chief Scientific & Med Officer	C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
John Leite	officer: Chief Commercial Officer-CLIA	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Evan/ Fa Jones	director	C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
John L Bishop	director
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Bonnie H Anderson	director, officer: President & CEO	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Karin Eastham	director	C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Giulia C Kennedy	officer: Chief Scientific & Med Officer	338 MAIN STREET #26E, SAN FRANCISCO CA 94105
Eliav Barr	director	C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Jens Holstein	director	C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Marc Stapley	officer: Chief Executive Officer	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Kevin K Gordon	director	155 S LIMERICK RD, LIMERICK PA 19468
Jonathan Wygant	officer: VP, Chief Accounting Officer	3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Annie Mcguire	officer: SVP, General Counsel	C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Rebecca Chambers	officer: Chief Financial Officer	3052 ORCHARD DR., SAN JOSE CA 95134